Kailera Therapeutics Raises $400M in Series A Financing for Obesity Treatments, Ron Renaud as CEO

Oct 1, 2024, 11:30 AM

Kailera Therapeutics, an obesity treatment developer, has raised $400 million in a Series A financing round. The startup, previously known as 'Hercules CM NewCo,' is led by CEO Ron Renaud, who has a track record of successful acquisitions. The funding round, announced on Tuesday, was backed by Atlas Venture, Bain Capital Life Sciences, and RTW Investments. This significant investment underscores the competitive nature of the obesity drug market, with Kailera Therapeutics aiming to advance its portfolio of next-generation therapies for obesity and related conditions. The company is already striking a deal for commercial manufacturing.